Venmax Drugs and Pharmaceuticals Ltd

Wed 23/09/2026,16:1:0 | BSE : VENMAX

₹16.292.30 (16.44%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 14.95

Previous Close

₹ 13.99

Volume

45330

Mkt Cap ( ₹ Cr)

₹ 14.31

High

₹ 16.70

Low

₹ 12.90

52 Week High

₹ 31.49

52 Week Low

₹ 12.71

Book Value Per Share

₹ 13.02

Dividend Yield

₹ 0.00

Face Value

₹₹10.00

What's Your Call?

Collective community sentiment on Venmax Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Venmax Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Venmax Drugs&Pharma. - NCLT Conveying Shareholder Meeting On October 24, 2026 At 12.30 P.M.

    22 Sep 2026, 10:13PM Venmax Drugs and Pharmaceuticals Limited has informed exchange about the meeting of equity shareholders of the Company pursuant to the order passed by
  • Venmax Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

    8 Sep 2026, 2:13PM Venmax Drugs and Pharmaceuticals Limited has informed the exchange about the update in respect of Scheme of Amalgamation of Hatri Pharma Private Limit
  • Venmax Drugs&Pharma. - Reg. 34 (1) Annual Report.

    1 Sep 2026, 4:41PM Submission of Annual Report for the Financial Year 2025-26 Pursuant to Regulation 34 and other relevant provisions of the SEBI (Listing Obligations &
  • Venmax Drugs&Pharma. - Board Meeting Outcome for Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India

    31 Aug 2026, 5:28PM Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we would like to inform you that a meeting of Boa
  • Venmax Drugs&Pharma. - Board Meeting Intimation for Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure

    24 Aug 2026, 12:51PM Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 ,inter alia,
  • Venmax Drugs&Pharma. Q1 net profit zooms 200.00% at Rs 0.12 cr

    22 Aug 2026, 4:00PM The company reported standalone net profit of Rs 0.12 crore for the quarter ended June 30, 2026 as compared to Rs 0.04 crore in the same period last y
  • Venmax Drugs&Pharma. - Statement Of Deviation & Variation

    7 Aug 2026, 5:26PM Statement of Deviation & Variation for the Quarter ended June 30, 2026.
  • Venmax Drugs&Pharma. - Unaudited Financial Results For The Quarter Ended June 30, 2026.

    7 Aug 2026, 5:05PM Unaudited Financial Results along with Limited Review Report for the Quarter ended June 30, 2026.
  • Venmax Drugs&Pharma. - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2026.

    7 Aug 2026, 4:56PM Unaudited Standalone Financial Results along with the Limited Review Report For the Quarter ended June 30, 2026.
  • Venmax Drugs&Pharma. - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30, 2026.

    1 Aug 2026, 3:42PM Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia,
  • Venmax Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Allotment

    30 Jul 2026, 4:15PM Allotment of 7,53,334 Convertible warrants in to Equity Shares on Preferential basis pursuant to Regulation 30 read with schedule III of SEBI LODR Reg
  • Venmax Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Allotment

    29 Jul 2026, 7:24PM Allotment of 21,47,665 Convertible warrants in to Equity shares on preferential basis pursuant to Regulation 30 read with Schedule III of SEBI LODR Re
  • Venmax Drugs&Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    17 Jul 2026, 2:00PM As of June 2026, 10.46% is owned by Indian Promoters and 89.54% by Public. <p align=justify> Top five Promoters holding highest number of shares of Ve
  • Venmax Drugs&Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    14 Jul 2026, 12:27PM Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

Key fundamentals

Evaluate the intrinsic value of Venmax Drugs and Pharmaceuticals Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 14.4471 4.4615 -0.298 -0.3624 -0.591
Liabilities 14.4471 4.4615 -0.298 -0.3624 -0.591
Equity 11.5829 5.2389 5.2389 5.2389 5.2389
Gross Profit 0.1206 -1.0601 -0.1045 -0.1855 -0.1273
Net Profit 0.2482 -0.0105 0.0645 0.2256 1.8462
Cash From Operating Activities -10.9961 -2.2902 0.0022 -0.0031 1.905
NPM(%) 3.09 -1.3 0 0 0
Revenue 8.0249 0.8073 0 0 0
Expenses 7.9043 1.8674 0.1045 0.1855 0.1273
ROE(%) 2.17 -0.09 0.56 1.97 16.14

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Venmax Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 871.35 2.55 22.22 7.98 -26.19 0.57
Lotus Eye Hospital and Institute Ltd 116.60 0.30 1646.29 29.09 0.39 0.00
Bharat Immunological and Biologicals Corporation Ltd 13.40 -4.08 0.00 60.41 -39.50 0.00
Astec Lifesciences Ltd 756.25 -4.74 0.00 31.17 -363.14 0.00

Company Info

Yenkey Drugs and Pharmaceuticals Ltd., was originally incorporated on 28th September, 1988 in the name of Yenkey Medico Drugs Private Limited. The Company has been converted into a public limited company on 3rd Feb'95 in terms of a special resolution passed on 23.01.95 under Section 31(1)/44 of the Companies Act, 1956. Accordingly the Company has obtained a fresh Certificate of Incorporation consequent on the conversion from the Registrar of Companies, Andhra Pradesh vide ref. no. 01-09102 dated 3rd February, 1995. The Company is producing bulk drug intermediates as detailed above and marketing in the domestic markets. The total turnover of the Company is Rs. 89.70 lacs for the year ended March 1994. Now the Company proposes to expand the existing capacity of dye and drug intermediate viz; ECA and diversifying into manufacturing of high value chemicals and bulk drugs viz; Sodium Azide and Vitamin B2 Phosphate. The Company is also proposing to set up a R & D Unit for maintaining high quality control standards of foreign buyers. 2009 -Company has changed its name from Yenkey Drugs and Pharmaceuticals Ltd. to Venmax Drugs & Pharmaceuticals Ltd. --Registered Office of the Company has been shifted from Plot No. 1-B12, 2nd floor, S.V.Co-operative Industrial Estate, Balanagar, Hyderabad - 500 037 to 8-3-319/3, Behind Sarathi Studio, Yellareddyguda, Hyderabad - 500 073. 2013 -Venmax Drugs and Pharmaceuticals Ltd has informed that Registered office has been shifted from "Plot No-35,Shivbagh Colony, Ameerpet, Hyderabad - 16" TO "H.NO 6-3-349/35, Flat No-21B, Dwaraka Avenue, DwarakaPuri Colony, Punjagutta, Hyderabad - 32". 2023 -Acquired Brownfield Hotel in Varanasi Uttar Pradesh and Aloft Bengaluru Whitefield Hotel in Karnataka. 2024 - Launched Raaya by atmosphere in Maldives. -Completed the Acquistion transaction pursuant to which our company directly/ indlrectly acquired - Aloft ORR Bengaluru, Anantara Maldives and Conrad Maldives.

Yenkey Drugs and Pharmaceuticals Ltd., was originally incorporated on 28th September, 1988 in the name of Yenkey Medico Drugs Private Limited. The Company has been converted into a public limited company on 3rd Feb'95 in terms of a special resolution passed on 23.01.95 under Section 31(1)/44 of the Companies Act, 1956. Accordingly the Company has obtained a fresh Certificate of Incorporation consequent on the conversion from the Registrar of Companies, Andhra Pradesh vide ref. no. 01-09102 dated 3rd February, 1995. The Company is producing bulk drug intermediates as detailed above and marketing in the domestic markets. The total turnover of the Company is Rs. 89.70 lacs for the year ended March 1994. Now the Company proposes to expand the existing capacity of dye and drug intermediate viz; ECA and diversifying into manufacturing of high value chemicals and bulk drugs viz; Sodium Azide and Vitamin B2 Phosphate. The Company is also proposing to set up a R & D Unit for maintaining high quality control standards of foreign buyers. 2009 -Company has changed its name from Yenkey Drugs and Pharmaceuticals Ltd. to Venmax Drugs & Pharmaceuticals Ltd. --Registered Office of the Company has been shifted from Plot No. 1-B12, 2nd floor, S.V.Co-operative Industrial Estate, Balanagar, Hyderabad - 500 037 to 8-3-319/3, Behind Sarathi Studio, Yellareddyguda, Hyderabad - 500 073. 2013 -Venmax Drugs and Pharmaceuticals Ltd has informed that Registered office has been shifted from "Plot No-35,Shivbagh Colony, Ameerpet, Hyderabad - 16" TO "H.NO 6-3-349/35, Flat No-21B, Dwaraka Avenue, DwarakaPuri Colony, Punjagutta, Hyderabad - 32". 2023 -Acquired Brownfield Hotel in Varanasi Uttar Pradesh and Aloft Bengaluru Whitefield Hotel in Karnataka. 2024 - Launched Raaya by atmosphere in Maldives. -Completed the Acquistion transaction pursuant to which our company directly/ indlrectly acquired - Aloft ORR Bengaluru, Anantara Maldives and Conrad Maldives.

Parent Organisation

Venmax Drugs & Pharmaceuticals Ltd.

Founded

28/09/1988

Managing Director

Mr.Venkata Rao Sadhanala

NSE Symbol

FAQ